Table 5 Subgroup analyses of primary endpoint for linagliptin versus total comparators based on Cox hazard model and CMH test
Linagliptin, patients with events/total patients | Total comparators, patients with events/total patients | Cox HR (95% CI) | CMH RR (95% CI) | |
|---|---|---|---|---|
Age (years)* | ||||
< 65 | 6/2390 | 9/1371 | 0.40 (0.14-1.14) | 0.49 (0.19-1.27) |
≥ 65 | 5/929 | 14/549 | 0.28 (0.10-0.79) | 0.43 (0.18-1.03) |
Gender | ||||
Male | 7/1782 | 20/1126 | 0.25 (0.10-0.60) | 0.31 (0.13-0.71) |
Female | 4/1537 | 3/794 | 0.96 (0.21-4.37) | 1.00 (0.32-3.17) |
Race | ||||
White | 8/1981 | 22/1187 | 0.28 (0.12-0.63) | 0.32 (0.15-0.70) |
Black | 0/46 | 0/31 | n.a. | 1.00 (0.29-3.50) |
Asian | 3/1292 | 1/702 | 1.63 (0.17-15.7) | 1.20 (0.34-4.26) |
Use of rescue medication | ||||
No | 8/3006 | 20/1666 | 0.29 (0.12-0.66) | 0.37 (0.17-0.80) |
Yes | 3/313 | 3/254 | 0.80 (0.16-3.96) | 0.91 (0.32-2.61) |
Investigator-reported hypoglycaemia* | ||||
No | 11/3048 | 16/1604 | 0.39 (0.18-0.86) | 0.45 (0.22-0.94) |
Yes | 0/271 | 7/316 | n.a. | 0.58 (0.13-2.58) |
Framingham 10-year CV risk score | ||||
≤ 15% | 4/2395 | 5/1323 | 0.50 (0.13-1.90) | 0.68 (0.24-1.95) |
> 15% | 7/923 | 18/597 | 0.31 (0.13-0.75) | 0.40 (0.18-0.90) |